Funding for this research was provided by:
National Institute of Mental Heath
Received: 22 September 2021
Revised: 5 January 2022
Accepted: 12 January 2022
First Online: 26 January 2022
: Dr. Achtyes has served on advisory boards for Alkermes, CAPNOS Zero (unpaid), Indivior, Janssen, Lundbeck/Otsuka, Neurocrine Biosciences, Roche, Sunovion and Teva and reports previous stock holdings in AstraZeneca, Johnson & Johnson, Moderna, and Pfizer. Dr. Achtyes has received research support from Alkermes, Astellas, Biogen, Boehringer-Ingelheim, InnateVR, Janssen, National Network of Depression Centers, Neurocrine Biosciences, Novartis, Otsuka, Pear Therapeutics, Takeda, and the Vanguard Research Group. All the other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.